Bovine virus vaccines that are liquid stable
The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
1. A liquid stable vaccine that comprises a live attenuated bovine virus, a 5-40% (w/v) sugar alcohol, and 0.15 to 0.75 M of an amino acid selected from the group consisting of arginine, glutamic acid, and glycine; wherein the liquid stable vaccine has a pH of 6.0 to 8.0; and
wherein the live attenuated bovine virus is selected from the group consisting of a bovine viral diarrhea virus (BVDV), an infectious bovine rinotracheitis virus (IBR), a parainfluenza type 3 virus (PI3), a bovine respiratory syncytial virus (BRSV), and any combination thereof.
2. The liquid stable vaccine of claim 1 wherein the sugar alcohol is sorbitol.
3. The liquid stable vaccine of claim 2 wherein the amino acid is arginine.
4. The liquid stable vaccine of claim 1 further comprising a sugar additive that is a non-sugar alcohol, wherein the total amount of the sugar alcohol and the non-sugar alcohol in the liquid stable vaccine is 10-40% (w/v).
5. The liquid stable vaccine of claim 1 wherein the non-sugar alcohol is selected form the group consisting of sucrose and trehalose.
6. The liquid stable vaccine of claim 1 that further comprises a component selected from the group consisting of an antioxidant, a surfactant, and a chelator.
7. The liquid stable vaccine of claim 1 that further comprises a buffer.
8. The liquid stable vaccine of claim 7 wherein the buffer comprises 2.5 to 50 mM potassium phosphate.
9. The liquid stable vaccine of claim 1 , wherein the amino acid is arginine.
10. The liquid stable vaccine of claim 3 , wherein the live attenuated virus is a BVDV selected from the group consisting of BVDV1, BVDV2, and BVDV1 and BVDV2.
11. The liquid stable vaccine of claim 10 that further comprises a live attenuated IBR.
12. The liquid stable vaccine of claim 11 that further comprises a live attenuated PI3.
13. The liquid stable vaccine of claim 12 that further comprises a live attenuated BRSV.
14. The liquid stable vaccine of claim 13 that further comprises a killed bovine virus.
15. The liquid stable vaccine of claim 13 that further comprises a bacterium.
16. The liquid stable vaccine of claim 15 wherein the bacterium is selected from the group consisting of a live attenuated or killed Pasteurella multocida, Mannheimia haemolytica, Histophilus somni, Mycoplasma bovis , and any combination thereof.
17. A method of vaccinating a bovine against bovine viral diarrhea virus (BVDV), infectious bovine rinotracheitis (IBR) virus, parainfluenza type 3 (PI3), and bovine respiratory syncytial virus (BRSV) comprising administering to the bovine the liquid stable vaccine of claim 13 .
18. A method of vaccinating a bovine against a bovine virus comprising administering to the bovine the liquid stable vaccine of claim 1 .
19. A method of making a liquid stable bovine vaccine that comprises combining a therapeutically effective amount of a live attenuated bovine virus with a 5-40% (w/v) sugar alcohol, 0.15 to 0.75 M arginine; wherein the live attenuated bovine virus is selected from the group consisting of a bovine viral diarrhea virus (BVDV), an infectious bovine rinotracheitis virus (IBR), a parainfluenza type 3 virus (PI3), a bovine respiratory syncytial virus (BRSV), and any combination thereof; and
wherein the liquid stable vaccine has a pH of 6.0 to 8.0.
20. The liquid stable vaccine of claim 2 , wherein the live attenuated virus is a BVDV selected from the group consisting of BVDV1, BVDV2, and BVDV1 and BVDV2.